Anika Therapeutics Inc (NASDAQ: ANIK) has reported E.P.S. of $-4.30 for its fourth fiscal quarter (ending December 31) versus $-0.34 for the same period a year ago. Relative to the consensus estimate of $-0.23, this was a shortfall of $-4.07. E.P.S. were $-5.64 for the latest four quarters through December 31 versus $-1.02 for the same period a year ago.
Recent Price Action
On 3/13/24, Anika Therapeutics Inc (NASDAQ: ANIK) stock declined modestly by -1.5%, closing at $25.40. Moreover, unusually high trading volume at 162% of normal accompanied the decline. Relative to the market the stock has been strong over the last nine months but has declined -3.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, ANIK is expected to continue to be Value Creation neutral.
Anika Therapeutics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Anika Therapeutics has a poor Appreciation Score of 22 but a slightly positive Power Rating of 63, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment